GT Biopharma, Inc. (NASDAQ:GTBP – Get Free Report) was the target of a large decrease in short interest in the month of July. As of July 15th, there was short interest totalling 16,500 shares, a decrease of 61.6% from the June 30th total of 43,000 shares. Based on an average daily trading volume, of 1,340,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.8% of the shares of the stock are short sold.
GT Biopharma Trading Up 0.5 %
Shares of GTBP stock traded up $0.01 during trading hours on Thursday, hitting $2.76. 4,869 shares of the company’s stock were exchanged, compared to its average volume of 625,997. The firm has a 50 day moving average of $3.24 and a two-hundred day moving average of $4.13. GT Biopharma has a fifty-two week low of $2.60 and a fifty-two week high of $10.66.
GT Biopharma (NASDAQ:GTBP – Get Free Report) last posted its quarterly earnings data on Wednesday, May 15th. The company reported ($2.12) EPS for the quarter, beating the consensus estimate of ($2.70) by $0.58.
Institutional Trading of GT Biopharma
About GT Biopharma
GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.
See Also
- Five stocks we like better than GT Biopharma
- How to Effectively Use the MarketBeat Ratings Screener
- Viking Therapeutics: Pharma Stock Soars on Positive Earnings
- Market Cap Calculator: How to Calculate Market Cap
- Top 3 Small Cap Stocks Emerging as Rotation Winners
- How to Most Effectively Use the MarketBeat Earnings Screener
- Bargain Alert: 3 Stocks Worth Watching While The Market Cools
Receive News & Ratings for GT Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GT Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.